These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 34186531)
21. Manualised cognitive-behavioural therapy in treating depression in advanced cancer: the CanTalk RCT. Serfaty M; King M; Nazareth I; Moorey S; Aspden T; Tookman A; Mannix K; Gola A; Davis S; Wood J; Jones L Health Technol Assess; 2019 May; 23(19):1-106. PubMed ID: 31097078 [TBL] [Abstract][Full Text] [Related]
23. Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. McIntyre RS; Rodrigues NB; Lipsitz O; Lee Y; Cha DS; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Ho R; Mansur RB; Rosenblat JD J Affect Disord; 2021 Jun; 288():210-216. PubMed ID: 33965843 [TBL] [Abstract][Full Text] [Related]
24. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101 [TBL] [Abstract][Full Text] [Related]
25. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans. Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335 [TBL] [Abstract][Full Text] [Related]
26. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study. Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635 [TBL] [Abstract][Full Text] [Related]
27. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118 [TBL] [Abstract][Full Text] [Related]
28. Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review. Dai D; Miller C; Valdivia V; Boyle B; Bolton P; Li S; Seiner S; Meisner R BMC Psychiatry; 2022 Feb; 22(1):140. PubMed ID: 35193541 [TBL] [Abstract][Full Text] [Related]
29. A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. Phillips JL; Jaworska N; Kamler E; Bhat V; Blier J; Foster JA; Hassel S; Ho K; McMurray L; Milev R; Moazamigoudarzi Z; Placenza FM; Richard-Devantoy S; Rotzinger S; Turecki G; Vazquez GH; Kennedy SH; Blier P; BMC Psychiatry; 2020 Jun; 20(1):268. PubMed ID: 32487236 [TBL] [Abstract][Full Text] [Related]
30. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416 [TBL] [Abstract][Full Text] [Related]
35. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469 [TBL] [Abstract][Full Text] [Related]
38. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965 [TBL] [Abstract][Full Text] [Related]
40. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]